Mizuho raised the firm’s price target on Kymera Therapeutics (KYMR) to $120 from $81 and keeps an Outperform rating on the shares. The firm sees the company’s KT-621 in atopic dermatitis data as “meaningfully de-risking” the program.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR: